FDA grants orphan drug designation to axatilimab for treatment of idiopathic pulmonary fibrosis (IPF)

Axatilimab is a monoclonal antibody that targets colony stimulating factor-1 receptor (CSF-1R). Pre-clinical models have shown a reduced number of disease-mediating macrophages and monocyte precursors shown to play a key role in the fibrotic disease process underlying diseases.

Source:

Biospace Inc.